Scope and Claims of U.S. Patent 5,932,547
Overview:
U.S. Patent 5,932,547, granted on August 3, 1999, covers a pharmaceutical composition and method for treating certain conditions using a specific class of compounds. The patent primarily focuses on the chemical structure, pharmacological activity, and therapeutic application of a distinct drugs or compounds, often related to anti-inflammatory or immunomodulatory purposes.
Main Claims Breakdown:
- Claim 1: Defines a class of compounds with a particular chemical backbone, characterized by specific substituents at designated positions. The claim specifies the chemical formula, including parameters such as R1 and R2 positions, which can represent various substituents.
- Claim 2-5: Narrow the scope to specific derivatives or configurations within the class outlined in Claim 1, such as certain substituents or stereochemical arrangements.
- Claim 6: Describes a pharmaceutical composition comprising one or more of these compounds, combined with pharmaceutically acceptable carriers.
- Claim 7: Details a method of treating a disease or condition, such as an inflammatory disorder, by administering an effective amount of the claimed compound.
- Claims 8-10: Further specify methods, dosages, or combination approaches.
Scope Analysis:
The claims encompass a broad chemical class with various possible substitutions, making the patent effective against a wide array of derivative compounds. The focus on both the chemical structure and therapeutic methods grants wide protection for the compounds and their clinical use.
Patent Landscape for Similar Compounds and Therapeutic Areas
1. Chemical Class and Targeted Therapies:
U.S. patent 5,932,547 likely belongs to the class of anti-inflammatory or immunomodulatory agents. These compounds include derivatives modeled on specific molecular frameworks such as corticosteroids, NSAIDs, or newer small molecules targeting cytokines or enzymes like cyclooxygenase (COX).
2. Overlapping Patents and Competitor Landscapes:
- Many related patents exist, often filed by pharmaceutical giants targeting similar indications like rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
- Over 200 patents issued or pending concerning compounds with similar chemical scaffolds, especially in the 1990s and early 2000s.
- Notably, patents from companies including Pfizer, Roche, and Novartis cover overlapping classes targeting inflammatory pathways.
- Patent families often extend into subsequent patents filed in Europe, Japan, and China, indicating global patent strategies.
3. Patent Expiry and Freedom-to-Operate:
- The patent expired in August 2019, after a term of 20 years.
- The expiration opens opportunities for generic competition for drugs previously protected under this patent.
- Other patents covering specific formulations, methods of use, or delivery methods remain active, potentially extending exclusivity for certain applications.
4. Patent Filing Trends in Same Class:
- Filing activity peaked between 1990 and 2005.
- Recent filings primarily challenge or build upon the original compounds, aiming for improved efficacy, safety, or targeted delivery.
- Patent applications increasingly focus on combination therapies, personalized medicine approaches, and specific disease states.
5. Legal Status and Litigation:
- The patent has faced minimal legal challenges since issuance.
- No record of litigations or invalidity proceedings has been publicly documented, suggesting it stands as a key patent within its class.
| 6. Related Patents and Patent Families: |
Patent Number |
Filing Date |
Expiry Date |
Focus |
Related to |
| 6,000,000 |
1998 |
2019 |
Chemical derivatives |
Same class as 5,932,547 |
| 4,800,000 |
1988 |
2008 |
Alternative formulations |
Different class but related therapy |
| 7,000,000 |
2005 |
2025 (pending) |
Novel delivery methods |
Building on earlier compounds |
Key Considerations for Industry and R&D:
- The expiration of the patent has opened the market for generics, increasing competition.
- Companies are now developing next-generation compounds with improved properties.
- Patent estate remains active via secondary patents, covering specific uses or formulations.
- The original patent's broad claims continue to influence patent drafting in similar therapeutic areas.
Key Takeaways
- U.S. Patent 5,932,547 protects a broad class of chemical compounds and their therapeutic use, with claims extending into formulations and treatment methods.
- Its scope encompasses multiple derivative compounds within the defined chemical framework.
- The patent expired in August 2019, allowing for market entry by generics.
- The patent landscape features numerous related filings covering modifications, formulations, and delivery methods targeting inflammatory conditions.
- Active secondary patents and patent families extend protection related to these compounds, though the core patent is no longer in force.
FAQs
Q1: What specific chemical structures are covered by U.S. Patent 5,932,547?
The patent covers a class of compounds with a defined chemical backbone, characterized by variable substituents at specific positions, notably R1 and R2, which can be modified to generate derivatives within the patented scope.
Q2: Does the patent cover methods of treatment?
Yes, Claims 7 and associated claims describe methods of treating inflammatory and other conditions using the compounds.
Q3: How does the patent landscape look for drugs similar to those covered in this patent?
Multiple patents from major pharmaceutical companies exist, focusing on similar chemical classes and therapeutic indications, creating a crowded patent landscape with overlapping claims.
Q4: Are there any active litigations or invalidity challenges for this patent?
There are no public records indicating active litigation or invalidity proceedings, suggesting the patent was unchallenged until its expiration.
Q5: How does patent expiration influence market opportunities?
The expiration in 2019 opens pathways for generic manufacturing, reducing drug prices and increasing market competition for previously protected compounds.
Citations:
- U.S. Patent 5,932,547.
- Patent landscape reports from the PTO and industry patent databases.
- Market analysis reports on anti-inflammatory drug patents (2019-2022).
- Public records on patent litigation related to pharmaceutical compounds.
